# Re-Aim Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/re-aim-therapeutics

- Industry: Biotechnology
- Headquarters: Oxford, UK
- Website: www.re-aimtx.com/
- Total disclosed funding: $9.3M
- Latest round: Seed (Oct 2, 2025)
- Investors on record: 2

## About

Based in Oxford, UK, and founded in 2024 by Chief Scientific Officer Asher Maroof, Founder of Re-Aim Therapeutics; co-founder details are not publicly disclosed in the reviewed official sources, Re-Aim Therapeutics operates as a biotechnology company developing therapies for autoimmune diseases by targeting and reducing specific T cell populations associated with disease activity. In May 2026, Re-Aim Therapeutics raised GBP 7 million in seed funding co-led by Syncona and Oxford Sciences Enterprises. Re-Aim Therapeutics focuses on developing targeted biologics for patients with T cell-driven autoimmune diseases. The company's offerings include monoclonal antibody candidates such as REA-001, designed to selectively deplete pathogenic T cells responsible for chronic inflammation. The firm provides a discovery platform that targets disease-relevant functional epitopes, enabling improved therapeutic selectivity. The company plans to use its proceeds from latest funding (May 2026) to advance its lead monoclonal antibody programmed REA-001 toward clinical development and expand its pipeline targeting autoimmune diseases.

## Funding rounds

- Seed, Oct 2, 2025, $9.3M — Syncona, Oxford Sciences Enterprises

## Investors

- Syncona (https://capitalatlas.ai/funds/syncona) — Seed
- Oxford Sciences Enterprises (https://capitalatlas.ai/funds/oxford-sciences-enterprises) — Seed